No Data
No Data
No Data
No Data
No Data
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (Vs US$46.29 Loss in FY 2022)
Yahoo FinanceApr 10 06:23 ET
RedHill Biopharma's Strategic Pivot and Financial Turnaround
TipRanksApr 8 10:27 ET
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure.
Investing.com Apr 8 09:42 ET
Express News | RedHill Biopharma FY23 EPS $0.01 Up From $(0.12) YoY Revenue $6.5M Down From $61.8M YoY
Moomoo 24/7Apr 8 09:26 ET
RedHill Biopharma 2023 Rev $6.5M >RDHL
RedHill Biopharma 2023 Rev $6.5M >RDHL
Dow JonesApr 8 09:24 ET
RedHill Biopharma Secures $1.25M in Direct Offering
TipRanksApr 4 16:57 ET
No Data
No Data